| Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC (NCT05239650) | Shanghai Henlius Biotech | 2022-07-15 |
| Microbiome in Colorectal Cancer Onset and Progression (NCT05368688) | Viome | 2022-06-30 |
| NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors (NCT05382377) | jianming xu | 2022-05-17 |
| Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening (NCT05314309) | The Netherlands Cancer Institute | 2022-03-25 |
| Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) (NCT05233332) | Shanghai Kechow Pharma, Inc. | 2022-02-24 |
| HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study (NCT05167071) | Harbour BioMed (Guangzhou) Co. Ltd. | 2021-12-28 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment (NCT04984369) | Shanghai Henlius Biotech | 2021-08-11 |
| Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (NCT04868773) | University of California, Irvine | 2021-07-16 |
| Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (NCT04808362) | Peptomyc S.L. | 2021-04-28 |
| Study to Evaluate D-1553 in Subjects With Solid Tumors (NCT04585035) | InventisBio Co., Ltd | 2020-10-02 |
| Evaluation of Bowel Cleansing Using the Pure-Vu System in Patients With History of Inadequate Bowel Preparation (NCT03922906) | Motus GI Medical Technologies Ltd | 2020-01-21 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (NCT03965845) | Calithera Biosciences, Inc | 2019-06-25 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313) | Calithera Biosciences, Inc | 2019-05-20 |
| Effect of WhatsApp Messenger on Uptake of CRC Screening Study (NCT03337776) | Chinese University of Hong Kong | 2019-02-01 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors (NCT03665285) | NextCure, Inc. | 2018-10-01 |
| A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC (NCT03601598) | Harbin Medical University | 2018-07-30 |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (NCT03597581) | Inspirna, Inc. | 2018-06-05 |
| Evaluation of the Performance of the Motus Cleansing System (MCS) (NCT03026075) | Motus GI Medical Technologies Ltd | 2016-12-22 |
| Addressing Colorectal Cancer in South Florida Firefighters (NCT05976282) | University of Miami | 2016-03-15 |
| Donation of Post Mortem Tumor Tissues (NCT03385980) | Niguarda Hospital | 2016-02-11 |
| Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System (NCT02572076) | Motus GI Medical Technologies Ltd | 2016-01-31 |
| Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer (NCT03336658) | Insel Gruppe AG, University Hospital Bern | 2015-10-01 |
| Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy (NCT02161549) | Motus GI Medical Technologies Ltd | 2012-07-01 |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma (NCT01394939) | Jennerex Biotherapeutics | 2012-01-01 |
| Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer (NCT01308086) | Hellenic Oncology Research Group | 2010-10-01 |